Europe
The listing of a minority of the unit, which makes X-ray and MRI machines, is set to take place in the first half of 2018.
A look at two biopharma companies that fall into this category that investors should check out.
The entire 1.2 million-square-feet facility is expected to be finished in 2030.
The deal was originally inked on Jan 17, 2014.
From 1997 through 2013, there was an average of 27 novel drugs approved in the U.S. per year.
The agency inspected the plant from May 15 to May 24, 2017, and observed that staffers at the plant were basically gaming the quality control system.
The new facility will add about 30 percent more capacity to Shire’s internal network.
Mallinckrodt picks up Sucampo’s Amitiza as well as two other pipeline compounds.
Italfarmaco has its eyes set on bringing a new treatment that targets the underlying mechanism of the blood disorder Polycythemia Vera.
PRESS RELEASES